DRTS News

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab